In focus · trending topic

menin-MLL inhibitor program

2 stories · following the connections

Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947

By Nasdaq OMXApr 7, 2017, 11:30 AM UTC

Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib

By Nasdaq OMXMar 6, 2017, 12:30 PM UTC